Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 117Triple Negative Breast Neoplasms 27Neoplasm Metastasis 18Sarcoma 17Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Brain Neoplasms 5Prostatic Neoplasms 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Liposarcoma 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Carcinoma, Transitional Cell 3Urethral Neoplasms 2Ureteral Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Recurrence 2Pancreatic Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2Leiomyosarcoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Advanced Breast Cancer 2

Interventions

pazopanib 2Ifosfamide 2Doxorubicin 2tremelimumab 1trametinib 1selinexor 1osimertinib 1eribulin 1durvalumab 1Sunitinib 1Proton Therapy 1Nivolumab 1Methotrexate 1HhAntag691 1Gemcitabine 1Epirubicin 1Dacarbazine 1Cisplatin 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangioendothelioma, Epithelioid × eribulin × Clear all
NCT03331250 2025-12-23

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Massachusetts General Hospital

Phase 2 Active not recruiting
13 enrolled 9 charts
Sarcoma

Hemangiosarcoma, Hemangioendothelioma, Epithelioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡